Fredrick Allen Hillis, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 374 S Shore Dr, Culver, IN 46511 Phone: 574-842-3706 Fax: 574-842-3706 |
News Archive
REGENERX BIOPHARMACEUTICALS, INC. announced today that researchers have correlated Tβ4 levels with the clinical course of patients with hepatitis B virus-related liver failure. It was reported that serum thymosin β4 levels were significantly lower in patients with chronic hepatitis B infection and that the magnitude of the reduction of thymosin β4 was closely related to the severity of the hepatic injury and to patient death. Since patients with higher Tβ4 levels survived the disease, changes in Tβ4 values could reflect outcome in some liver failure patients.
New research finds increasing age is a risk factor for decreased postpartum pelvic floor strength. The prospective study published in the March edition of Female Pelvic Medicine & Reconstructive Surgery, the official journal of the American Urogynecologic Society, the leading professional organization dedicated to the treatment of pelvic floor disorders.
Mast Therapeutics, Inc., a biopharmaceutical company developing novel, clinical-stage therapies for sickle cell disease and heart failure today announced that it has completed patient enrollment in its Phase 3 clinical study of vepoloxamer for the treatment of patients with sickle cell disease experiencing vaso-occlusive crisis, known as the EPIC study.
Mount Sinai School of Medicine researchers will present several landmark studies, including data on treatment trends in late-stage cancer, a promising multiple myeloma vaccine, and predictive models of soft tissue sarcomas, prostate and bladder cancer, at the 2012 American Society of Clinical Oncology (ASCO) meeting June 1-5, 2012 in Chicago.
› Verified 6 days ago